Daraxonrasib shows promising pancreatic cancer results as Chinese lung therapy exceeds expectations

The latest ASCO updates highlighted detailed data on daraxonrasib, a drug targeting pancreatic cancer, indicating encouraging efficacy signals for patients.

In parallel, a lung cancer treatment developed in China continued to outperform prior benchmarks, reinforcing its potential in the market.

Eli Lilly also disclosed two new partnership agreements in China, while Akeso reported a notable payoff from its lung cancer bispecific program. Additionally, a long‑standing peptide popular among biohackers has drawn regulatory scrutiny from the FDA.